VJHemOnc is committed to improving our service to you

ASCO 2020 | EVOLVE: Orva-cel in RRMM

VJHemOnc is committed to improving our service to you

Sham Mailankody

Sham Mailankody, MBBS, Memorial Sloan Kettering Cancer Center, New York City, NY, USA, discusses data from the EVOLVE phase 1/2 study (NCT03430011) of orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR-T cell therapy, in patients with relapsed/refratory multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter